M5049 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	2

49. Systemic lupus erythematosus

---

Clinical trials : 946 /  Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05162586 (ClinicalTrials.gov)	December 17, 2021	8/12/2021	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)	A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)	Systemic Lupus Erythematosus	Drug: M5049 low dose;Drug: M5049 medium dose;Drug: M5049 high dose;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not yet recruiting	18 Years	75 Years	All	440	Phase 2	United States;Germany
2	NCT04647708 (ClinicalTrials.gov)	December 16, 2020	23/11/2020	Study of M5049 in CLE and SLE Participants	A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in SLE and CLE Participants Treated With Standard of Care	Systemic Lupus Erythematosus;Cutaneous Lupus Erythematosus	Drug: M5049;Drug: Placebo	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NULL	Recruiting	18 Years	65 Years	All	44	Phase 1	Bulgaria;Germany;Moldova, Republic of;Spain;Ukraine